tbuckley/cabot-search huggingface dataset:
Book Review Bibliographia Primatologica: A classified bibliography of primates other than man. Part 1. Anatomy, embryology and quantitative morphology; physiology, pharmacology and psychobiology; primate phylogeny and miscellanea . By Theodore C. Ruch, B.Sc., Ph.D. With an introduction by John F. Fulton, M.D., Ph.D. 4°, cloth, 241 pp. Springfield, Illinois: Charles C Thomas, 1941. $8.50.
Journal: New England Journal of Medicine (1942)
Maine company falls a-fowl for smuggling bird flu
Authors: Emily Singer
Journal: Nature Medicine (2005)

Maine company falls a-fowl for smuggling bird fluAs the virulent bird flu sweeping through Asia holds global attention, regulators in Maine are dealing with an avian virus closer to home.A Maine biotechnology company that makes vaccines for poultry diseases was in August fined $500,000 for smuggling a chicken flu virus into the US.Vaccine manufacturer Maine Biological Labs in 1998 illegally imported the virus from Saudi Arabia so that it could develop a vaccine for a disease-plagued poultry farm in that country.According to court records, the following year the company used falsified documents to send 8,000 bottles of the newly created vaccine back to Saudi Arabia."If the virus got out, it could have decimated poultry populations and cost billions of dollars," says Keith Haffer, a vaccine consultant at
Abstract 3892: Population pharmacokinetics of siltuximab: An analysis across tumor types
Authors: Mina Nikanjam, Jin Yang, Edmund V. Capparelli
Journal: Cancer Research (2019)

Abstract Introduction: Siltuximab is an IL-6 inhibiting monoclonal antibody which has been studied in solid tumors and hematologic malignancies, but no comprehensive pharmacokinetic (PK) analysis has been conducted to determine the impact of disease on siltuximab disposition. Methods: Siltuximab pharmacokinetic data from 7 Phase I and II clinical trials included healthy subjects, Castleman’s disease, ovarian cancer, non-Hodgkin’s lymphoma, multiple myeloma, smoldering multiple myeloma, chronic lymphocytic leukemia, renal cell carcinoma, and solid tumors with KRAS mutations. Siltuximab was most commonly dosed at 11 or 15 mg/kg (range 1 - 20 mg/kg) with 70% of patients receiving multiple doses. Plasma samples were obtained 0.33 h - 27 weeks after dosing with siltuximab concentrations determined using a validated ELISA assay. The PK analysis was performed using nonlinear mixed effects modeling (NONMEM 7.3) and included data from 465 subjects (7,761 samples). Results: Siltuximab concentration data was best fit with a two-compartment model. Healthy volunteer status (HV), Castleman’s disease (CD), albumin (ALB), and ALT were independent predictors of clearance (CL), while ALB, HV, serum creatinine (SCR), weight (WT), and smoldering multiple myeloma predicted volume of distribution (Vdss). There was no impact of dose level on CL or Vdss. In the final PK model CL was described as: CL (mL/hr) = 8.93 x (ALB/4.1)-0.843 x (ALT/17)-0.0964 x 1.24 (if HV) x 0.765 (if CV); between subject variability was 41.0%. The final model was used to simulate a dose of 11 mg/kg for 1000 subjects with the median (IQR) exposure (AUC) and CL as follows: CL (mL/hr)AUC (mcg*day/mL)Half-lifeβ (days)Healthy volunteers6.61 (4.99 – 8.63)4,855.8 (3,717.4 - 6,426.3)24.5 (19.2 – 33. 6)Castleman’s Disease11.11 (8.48 - 14.36)2,884.3 (2,233.7 - 3,782.5)19.1 (14.6 - 25.0)Other tumor types9.13 (6.93 - 11.52)3,514.5 (2,786.2 - 4,627.0)22.2 (17.5 - 30.5) Conclusions: This combined population PK analysis demonstrates that clearance can differ with disease type consistent with previously published variations in IL-6 activity. These population differences along with significant between subject variability suggest that clinical and disease factors influence siltuximab disposition and may need to be considered in dosing requirements. Citation Format: Mina Nikanjam, Jin Yang, Edmund V. Capparelli. Population pharmacokinetics of siltuximab: An analysis across tumor types [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3892.
THE UNITED STATES PUBLIC HEALTH AND MARINE-HOSPITAL SERVICE.PART II. THE SERVICE AS IT IS TO-DAY.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chronic synovitis in gout simulating rheumatoid arthritis. Demonstration of bilateral popliteal cysts and wrist synovial corrugation
Authors: E. D. Trentham
Journal: JAMA (1976)

A PATIENT had gouty arthritis closely simulating rheumatoid arthritis clinically and on plain-film examination. Serial arthrographic study showed persistent, generalized, synovial corrugation of the wrists and large popliteal cysts of both knees. These arthrographic features, typically associated with rheumatoid arthritis,<sup>1-3</sup>provide evidence for a rheumatoid-like chronic uratic synovitis in gout. Chronic synovial inflammation, rather than tophus deposition in avascular paraarticular structures,<sup>4</sup>may account for instances of roentgenographic mimicry of rheumatoid arthritis by gout,<sup>5</sup>and this mechanism should be considered in determining the pathogenesis of joint lesions typically associated with gout. Finally, this case illustrates the occasional difficulty, especially in older patients, in distinguishing clinically as well as roentgenographically these two synovial inflammatory diseases that are believed to be mutually exclusive, almost without exception.<sup>4</sup> <h3>Report of a Case</h3> A 66-year-old retired soldier reported a chronic, symmetrical, progressive polyarthritis of his knees, wrists, elbows, and proximal interphalangeal joints
Palliative side-to-side oesophagogastrostomy for unresectable carcinoma of the oesophagus and cardia
Journal: Thorax (1981)

of Dr Fred Rosner's authoritative paper, in your April issue, on Moses Maimonides' Treatise on Asthma refers to "a briefbiographical section", which does not appear to be included in the text.May I therefore be permitted to provide a few details of the life of Maimonides, who was physician to princes, and was described by Sir William Osler as "the prince of physicians".Moses Maimonides was born on 30 March 1135 in Cordoba, in Moorish Spain, which was at that time a great seat of Jewish learning.There is now in Cordoba a charming statue of Maimonides situated near his birthplace.Maimonides was descended from an intel- lectually aristocratic family of Jewish scholars, and his father was Rabbi Maimon.When Moses himself later became a Rabbi, he was known as Rabbi Moses ben Maimon, the initials of which R'M'B'M led to him being referred to as the RAMBAM.Maimon-ides is the Greek version, meaning the son of Maimon.As a lad Maimonides' brilliance was soon demon- strated by his mastery of Hebrew, Arabic, and Spanish Christian writings.
American Climatological Association.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lithium Dermatitis
Authors: Ramón Ruíz-Maldonado
Journal: JAMA (1973)

<h3>To the Editor.—</h3> Cutaneous reactions to lithium carbonate were reported by Posey (221:1517, 1972) as a papular, pruritic dermatitis on the elbows of a woman. Kurtin (223:802, 1973) reported asymptomatic, hyperkeratotic, erythematous, follicular papules on the extensor surfaces of the arms and legs and sometimes on the trunk in 17 patients. Callaway, quoted by Kurtin, reported pruritic maculopapular eruptions and cutaneous ulcers of the lower extremities in five patients. We want to report the case of a 28-year-old woman with manicdepressive psychosis since December 1971; she was first treated with chlorpromazine and thioxanthens for four months with poor results. Since May 1972 she has been treated exclusively with lithium carbonate. Serum levels of 0.9 mEq/liter were obtained with a daily dose of 900 mg. One month after the initiation of therapy, she had a severe acneiform eruption on the face and shoulders. At her own risk, the patient stopped taking
Surgical Obstetrics
Authors: Lionel J. Schewitz
Journal: JAMA (1993)

Surgical obstetric knowledge and skill is basic to the well-rounded obstetrician, and the surgical obstetric textbook should, above all, be a lucid and precise recipe for the safe execution of practical maneuvers in obstetrics. The profession has been fortunate in having, since the advent of the accoucheur, a fine tradition of well-written, practical textbooks. The book under review, however, while fulfilling most of the requirements of up-to-date completeness and practicality, has some disappointing lapses, which will be described later. In his preface, Dr Plauché focuses on the widespread concern that, in our present litigious climate, which has led to increasing reliance on abdominal delivery, the skills of complex vaginal delivery are being neglected in teaching, and he argues for a renaissance of these skills. In a useful chapter on clinical competence in obstetric surgery, he makes a penetrating analysis of the elements of successful teaching and explores methods of assessment
Subject Index
Authors: Giovanni A. Fava, Hellmuth Freyberger, Harald-J. Freyberger, Julian Iancu, Moshe Kotler, Baruch Spivak, Margaret Radwan, Avraham Weizman, K. Lovell, I.M. Marks, H. Noshirvani, G. O'Sullivan, Mark A. Lumley, Karen Downey, Laurence Stettner, Francine Wehmer, Ovide F. Pomerleau, Per Høglend, Oscar Heyerdahl, Thomas Middelboe, Lars Ovesen, Erik Lykke Mortensen, Per Bech, M. Ercolani, G. Trombini, R. Chattat, C. Cervini, G. Piergiacomi, F. Salaffi, S. Zeni, R. Marcolongo, Lluisa Garcia, Manuel Valdés, Inmaculada Jódar, Nadine Riesco, Tomás de Flores, Giulia Perini, Michele Zara, Roberto Cipriani, Christian Carraro, Antonio Preti, Franco Gava, Paola Coghi, Andrea Peserico, O. Todarello, A. Casamassima, M. Marinaccio, M.W. La Pesa, L. Caradonna, L. Valentino, L. Marinaccio, Vanja Blomkvist, Töres Theorell, Hans Jonsson, Sam Schulman, Erik Berntorp, Lennart Stiegendal, Joel A. Pava, Maurizio Fava, Janet A. Levenson
Journal: Psychotherapy and Psychosomatics (1994)
Tests of blood coagulation and hemostasis. 3. The partial thromboplastin time
Authors: P. Didisheim
Journal: JAMA (1967)

Previous articles in this series have dealt with the prothrombin time (PT) and the coagulation time (CT).<sup>1,2</sup>For many years these were the only tests available for the detection of clotting disorders. With the development of the thromboplastin generation test (TGT) and the partial thromboplastin time (PTT<sup>3,4</sup>), clinically important clotting defects which previously went undetected now can be identified. The TGT and PTT are not substitutes for the PT; they are sensitive to different clotting factors. However, the use of the TGT and PTT has largely done away with the usefulness of the Lee-White test. Even when the CT is made more sensitive by the use of tubes coated with silicone, the test remains less sensitive to mild clotting disorders than the TGT or PTT (unpublished data). In addition, for the detection of clinically significant deficiencies of factor VIII (antihemophilic factor) or IX (plasma thromboplastin component), the PTT
THE FATE OF THE LYMPHOCYTES
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of Yellow Fever
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Occupational Exposure to Environmental Tobacco Smoke
Authors: Michael W. Ogden
Journal: JAMA (1996)

<h3>To the Editor.</h3> —The article by Dr Hammond and colleagues<sup>1</sup>appears to contain a serious error in data calculation. The authors state that passive monitors for nicotine were exposed for "1 week." Assuming this means 7 days, the monitors were exposed for a period of 168 hours. However, it appears that the authors used only 45 hours in the calculation of airborne nicotine concentration (with the possible exception of samples acquired at "fire stations"). If so, correcting this miscalculation significantly alters the conclusions with respect to potential worker risk as stated in their article and in the accompanying American Medical Association news release. All official analysis methods of which I am aware (National Institute for Occupational Safety and Health, Occupational Safety and Health Administration, Environmental Protection Agency, American Society for Testing and Materials, International Standards Organization, Association of Official Analytical Chemists, etc) require that airborne concentration be calculated using
HEALTH OF ITALIAN IMMIGRANTS.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TREPHONES—GROWTH-PROMOTING SUBSTANCES
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Beneficial effects of treatment of nicotine dependence during an inpatient substance abuse treatment program
Authors: A. M. Joseph
Journal: JAMA (1990)

The Minneapolis Department of Veterans Affairs Medical Center began an intervention for tobacco use in its inpatient substance dependency treatment program on June 19, 1988, including an institutional smoke-free policy and a smoking cessation program. Sequential substance-dependent patients admitted before institution of the policy (n = 455) were compared with patients admitted after institution of the policy (n = 457). Patients completed self-administered questionnaires regarding smoking practices and attitudes. Seventy-six percent of patients were current cigarette smokers. Fifty-eight percent of patients after institution of the policy described themselves as "not smoking regularly," compared with 19% of patients admitted before the institution of the policy. Similar proportions of patients admitted before and after the institution of the policy believed that quitting smoking would threaten recovery. Forty-one percent of patients hospitalized after institution of the policy abstained from smoking for more than 1 week during their hospital stay. Rates of early termination of treatment did not change. We conclude that concurrent intervention for nicotine addiction during inpatient treatment of substance dependence is associated with a temporary reduction in smoking and increased motivation to quit smoking. (<i>JAMA</i>. 1990;263:3043-3046)
A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer.
Authors: Jun Horiguchi, Yoshie Hasegawa, Daishu Miura, Takashi Ishikawa, Mitsuhiro Hayashi, Shintaro Takao, Seung Jin Kim, Hirokazu Tanino, Masaru Miyashita, Muneharu Konishi, Yasushi Shigeoka, Kazuhiko Yamagami, Kohei Akazawa, Norio Kohno
Journal: Journal of Clinical Oncology (2013)

1029 Background: Zoledronic acid (ZOL) has been found to have a synergistic anti-proliferative effect when used in combination with antitumor drugs. We investigated the synergistic effect of ZOL, assessed by pathological complete response (pCR) rate, when added to neoadjuvant chemotherapy (CT) in the primary tumor. Methods: Women with resectable invasive Stage IIA-IIIB breast cancer who are HER2-negative, between 20 and 70 years of age, and ECOG PS 0-1 were eligible. CT regimen was FEC100 q3w × 4 cycles followed by weekly paclitaxel for 12 cycles. ZOL 4mg was administered every 3-4 weeks, a total of 7 times. Patients were randomized 1:1 to the ZOL group or CT group, according to the presence or absence of lymph node metastasis, estrogen receptor (ER) status, and menopausal status. The primary endpoint was the rate of pCR defined as absence of invasive disease in the breast at surgery. The planned sample size was 180 patients. Results: 188 patients were recruited between March 2010 and April 2012; however 10 patients were excluded from the primary assessment. The overall pCR rate was 14.8% and 7.8% in the ZOL and CT groups, respectively (p=0.160). In the postmenopausal patients, pCR rate was 18.4% and 5.4% in the ZOL and CT groups, respectively (p=0.153). In the triple-negative patients, pCR rate was 35.3% and 11.8% in the ZOL and CT groups, respectively (p=0.225). In the postmenopausal and triple-negative patients, pCR rate was 50.0% and 0% in the ZOL and CT groups, respectively (p=0.077). There was no significant difference in severe toxicity between the two groups. Conclusions: The results of this trial suggest that the addition of ZOL to neoadjuvant CT has potential anti-cancer benefit in patients with postmenopausal and triple-negative breast cancer. Further investigation will be warranted. Clinical trial information: 000003261.